drugset

drugset / Trial / NCT05848843

A Phase I Study of Adagrasib and Durvalumab for Treatment of Advanced Non-small Cell Lung Cancers and Gastro-intestinal Cancers Harboring KRAS G12C Mutations

NCT05848843 ↗

Phase 1 Withdrawn M.D. Anderson Cancer Center AstraZeneca · collab Mirati Therapeutics Inc. · collab

RandomizedSingle-groupOpen-labelTreatment

Summary

To find a recommended dose of the combination of adagrasib and durvalumab that can be given to patients with cancers that have a KRAS G12C mutation.

Timeline

Start: 2023-04-25
Primary completion: 2024-01-16
Completion: 2024-01-16

Publications

Luo J, Florez N, Donnelly A, Lou Y, Lu K, Ma PC, Spira AI, Ryan D, Husain H. Adagrasib Treatment After Sotorasib-Related Hepatotoxicity in Patients With KRASG12C-Mutated Non-Small Cell Lung Cancer: A Case Series and Literature Review. JCO Precis Oncol. 2024 Apr;8:e2300644. doi: 10.1200/PO.23.00644.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Adagrasib	Small molecule	—	Oral
Subject	Durvalumab	Monoclonal antibody	—	Intravenous

Indications